Here are the 10-Q quarterly reports from Voyager Acquisition Corp (VACH) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VACH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VACH filings page.
Voyager Acquisition Corp. reported first-quarter 2026 results as a pre‑combination SPAC, with total assets of $272.3 million, almost entirely in a Trust Account invested in a money market fund.
Net income was $180,498 for the three months ended March 31, 2026, driven by $2.37 million of income from investments held in the Trust Account, partly offset by $2.19 million of general and administrative expenses.
The planned business combination with Veraxa Biotech AG advanced: the Form F‑4 was declared effective and shareholders approved the transaction, with implied merger consideration of approximately $1.35 billion. However, approximately 25,217,315 Class A shares, or about 99.67% of public shares, elected redemption, leaving an estimated 82,685 public shares and about $885,556 expected to remain in the Trust Account after paying redemptions. Voyager ended the quarter with cash of $32,790 outside the Trust Account and a working capital deficit of $3.29 million, and management disclosed substantial doubt about its ability to continue as a going concern absent completion of the business combination or additional financing.
Voyager Acquisition Corp. reported net income of $7.3 million for the nine months ended September 30, 2025, mainly from $8.2 million of income on investments in its $267.3 million trust account, while general and administrative expenses were $0.9 million. The SPAC completed its August 2024 IPO of 25,300,000 units at $10.00 each, plus a $7.7 million private warrant placement, and now holds essentially all assets in a money market fund within the trust. On April 22, 2025, Voyager signed a Business Combination Agreement with Veraxa Biotech AG using a Swiss “PubCo” and Cayman Merger Sub in a two-step merger structure. As of September 30, 2025, cash outside the trust was $252,350 with a working capital deficit of about $0.2 million, and management highlighted substantial doubt about the company’s ability to continue as a going concern given its August 12, 2026 mandatory liquidation deadline if no business combination is completed.